First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Biotechnology

Healthcare
$44.50 -4.87%

-$0.89 today

Market cap
$1.87B
Beta
0.00
P/E (TTM)
-6.1
EPS (TTM)
-$2.81
52W Low $14.72High $26.80

Volume 0.75M

Average 0.43M

Balance Sheet

Inspect the capital base behind the business.

Assets

$330.55M

FY 2025 · Annual

-25.2% YoY

Liabilities

$43.05M

FY 2025 · Annual

-14.4% YoY

Equity

$287.49M

FY 2025 · Annual

-26.6% YoY

Balance Sheet

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents35.97M123.08M238.2M
Short-term Investments354.94M262.29M73.44M
Net Receivables000
Inventory000
Other Current Assets000
Total Current Assets398.56M389.93M316.4M
Property, Plant & Equipment (Net)18.27M16.23M13.89M
Goodwill000
Intangible Assets000
Long-term Investments27.03M35.47M0
Tax Assets000
Other Non-current Assets256K256K256K
Total Non-current Assets45.55M51.96M14.15M
Total Assets444.11M441.89M330.55M
Account Payables2.43M3.79M3.11M
Short-term Debt000
Tax Payables000
Deferred Revenue000
Other Current Liabilities4.59M7.42M0
Total Current Liabilities18.22M36.18M31.02M
Long-term Debt000
Deferred Tax Liabilities000
Deferred Revenue (Non-current)000
Other Non-current Liabilities000
Total Non-current Liabilities16.04M14.11M12.03M
Total Liabilities34.26M50.3M43.06M
Common Stock410.65M391.29M287.51M
Retained Earnings000
Accumulated OCI(797K)305K(24K)
Other Stockholders Equity000
Minority Interest000
Total Equity409.85M391.6M287.49M
Total Debt17.81M16.04M14.11M
Net Debt(18.15M)(107.04M)(224.08M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$248.5M
Short-term Investments$38.0M
Other Current$2.9M
Total Current Assets$289.4M
PP&E (Net)$1.2M
Total Non-current Assets$1.2M
Total Assets$290.6M

Analysis

Selected assets total $290.6M for Latest. The largest visible component is Cash & Equivalents at $248.5M, about 85.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 12, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
424B3424B3 filingNov 4, 2026
424B3424B3 filingNov 4, 2026
4Statement of changes in beneficial ownershipNov 3, 2026

How much cash does TRAX have?

First Tracks Biotherapeutics Inc (TRAX) reported $238.20M in cash and equivalents in fiscal 2025.

How much debt does TRAX carry?

First Tracks Biotherapeutics Inc (TRAX) reported $14.11M of total debt, with net debt of -$224.08M.